Rytary (levodopa/carbidopa extended-release capsule) / Amneal  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rytary (levodopa/carbidopa extended-release capsule) / Amneal
NCT00869791: A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa

Completed
2
27
US
IPX066, ER CD-LD, IR CD-LD, immediate-release carbidopa-levodopa
Impax Laboratories, LLC
Parkinson's Disease
06/09
06/09
NCT02271503: A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Completed
2
26
US
CD-LD IR, Sinemet, IPX203 180 mg, CD-LD ER 180 mg, IPX203 270 mg, CD-LD ER 270 mg, Rytary 195 mg, Rytary 145 mg
Impax Laboratories, LLC
Parkinson's Disease
08/16
08/16

Download Options